Login to Your Account


European regulations preventing lift-off for advanced therapies?

By Cormac Sheridan
Staff Writer

Tuesday, April 14, 2015
PARIS – Refinement of the EMA's rules for advanced therapy medicinal products (ATMPs), which came into effect in 2009, is ongoing, but, so far at least, there is little evidence to suggest that the legislation has been an enabler for companies developing cell therapies or gene therapies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription